Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.

Menopause represents the physiological transition when a woman's reproductive period ends associated with a variety of symptoms, including vasomotor symptoms, such as night sweats and hot flashes. This systematic review and meta-analysis aimed to assess the effectiveness and safety of oral Fezolinetant for treating vasomotor symptoms associated with menopause. Five electronic databases were searched from their inception until May 2023. Via the Cochrane risk of bias tool, two reviewers assessed the studies' quality. The primary outcomes were a decrease in VMSs frequency and severity and safety outcomes at 4 and 12 weeks. Data were extracted and then analyzed using RevMan software. This meta-analysis included six trials with a total of 3291 women that compared Fezolinetant to a placebo in the treatment of menopausal VMSs. After 4 and 12 weeks of therapy, fezolinetant at 30 mg QD or 45 mg QD substantially decreased the frequency and severity of VMSs per 24 hours compared to placebo. Fezolinetant at 90 mg BID, 30 mg QD, or 45 mg QD did not show a significant difference in the rate of treatment-emergent adverse events (TEAEs), headache, and TEAEs leading to permanent discontinuation compared to placebo. Fezolinetant proves to be a successful and well-tolerated remedy for menopausal women suffering from VMSs. Notably, the 45 mg daily dosage over 12 weeks exhibited significant efficacy. Nonetheless, extensive future trials are necessary to ascertain its long-term safety, effectiveness, and relative potency compared to alternative VMS treatments like hormone therapy.

La ménopause représente la transition physiologique lorsque la période de reproduction d'une femme se termine, associée à divers symptômes, notamment des symptômes vasomoteurs, tels que des sueurs nocturnes et des bouffées de chaleur. Cette revue systématique et méta-analyse visaient à évaluer l'efficacité et l'innocuité du Fezolinetant oral pour traiter les symptômes vasomoteurs associés à la ménopause. Cinq bases de données électroniques ont été consultées depuis leur création jusqu'en mai 2023. Via l'outil Cochrane sur le risque de biais, deux examinateurs ont évalué la qualité des études. Les principaux critères de jugement étaient une diminution de la fréquence et de la gravité des SVM ainsi que des critères de sécurité à 4 et 12 semaines. Les données ont été extraites puis analysées à l'aide du logiciel RevMan. Cette méta-analyse comprenait six essais portant sur un total de 3 291 femmes comparant Fezolinetant à un placebo dans le traitement des SVM ménopausiques. Après 4 et 12 semaines de traitement, le fézolinetant à la dose de 30 mg une fois par jour ou de 45 mg une fois par jour a considérablement réduit la fréquence et la gravité des SMV toutes les 24 heures par rapport au placebo. Le fézolinetant à la dose de 90 mg deux fois par jour, de 30 mg une fois par jour ou de 45 mg une fois par jour n'a pas montré de différence significative dans le taux d'événements indésirables survenus pendant le traitement (TEAE), de maux de tête et de TEAE conduisant à un arrêt définitif par rapport au placebo. Le fézolinetant s'avère être un remède efficace et bien toléré pour les femmes ménopausées souffrant de VMS. Notamment, la dose quotidienne de 45 mg sur 12 semaines a montré une efficacité significative. Néanmoins, de futurs essais approfondis sont nécessaires pour vérifier son innocuité, son efficacité et sa puissance relative à long terme par rapport aux traitements alternatifs du VMS comme l'hormonothérapie.

Knowledge and attitudes of nurses toward sickle cell disease patients in Jazan.

Background: In this study, we look at the role of nurses in dealing with sickle cell disease (SCD) patients in Jazan city. Objectives: The aim of this study was to determine the knowledge of nurses and their attitudes toward SCD patients in Jazan hospitals, Saudi Arabia. Materials and Methods: In this cross-sectional, hospital-based study, based on the inclusion and exclusion criteria, we recruited 240 nurses from Prince Mohammed bin Nasser and Jazan general hospitals in Jazan city, Saudi Arabia. We depend on the validity and reliability of the instrument that were done by the author who prepared the tool of the primary research, and data management processing was incorporated. Statistical analysis was performed with the obtained data. Results: In this study, 24.2% of males and 75.8% of females were included. Of these, 40.4% of nurses between 35 and 40 years of age. About 50.4% has 10-15 years of working experience. 5% of the study participants' salary is equal to 5000 SR which is the lower salary in the group of the participants. Also, 54.6% of nurses had a bachelor's degree, 32.9% had a diploma, and only 12.5% had a master's degree. Approximately 65% of nurses were married. Around 52% of nurses knew that SCD patients should have daily intake of 3 l of liquid and 44% of them recommended pop, juice, and broth. Among the sociodemographic variables, gender and income source were associated with attitude and knowledge scales, whereas among nurses' groups, only marital status was associated (P < 0.05). Also, among the sociodemographic variables of nurses, There is statistically significant relation between the nurses' knowledge and attitude and the demographic characteristics such as income levels, marital status and experiences as revealed by P.vale <0.05. In this study, 72.5% of nurses had poor knowledge score levels and 27.5% had good knowledge. Conclusion: This study concludes that the average total knowledge score was 8.41 and only 27.5% of nurses had good knowledge about SCD in Jazan region. This study also suggests increasing educational interventions, which could aid in improving nurses' knowledge and attitudes toward SCD. It is recommended to conduct a similar study with a large number of professionals in order to generalize the findings.